High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.

MLA

Shiba, Norio, et al. “High PRDM16 Expression Identifies a Prognostic Subgroup of Pediatric Acute Myeloid Leukaemia Correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: The Results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 Trial.” British Journal of Haematology, vol. 172, no. 4, Feb. 2016, pp. 581–91. EBSCOhost, https://doi.org/10.1111/bjh.13869.

APA

Shiba, N., Ohki, K., Kobayashi, T., Hara, Y., Yamato, G., Tanoshima, R., Ichikawa, H., Tomizawa, D., Park, M.-J., Shimada, A., Sotomatsu, M., Arakawa, H., Horibe, K., Adachi, S., Taga, T., Tawa, A., & Hayashi, Y. (2016). High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. British Journal of Haematology, 172(4), 581–591. https://doi.org/10.1111/bjh.13869

Chicago

Shiba, Norio, Kentaro Ohki, Tohru Kobayashi, Yusuke Hara, Genki Yamato, Reo Tanoshima, Hitoshi Ichikawa, et al. 2016. “High PRDM16 Expression Identifies a Prognostic Subgroup of Pediatric Acute Myeloid Leukaemia Correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: The Results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 Trial.” British Journal of Haematology 172 (4): 581–91. doi:10.1111/bjh.13869.